Features and expert interviews

Christel Hendrieckx discusses the psychological consequences of hypoglycemia in people with diabetes (22:46).

William Polonsky talks about how diabetes distress affects the wellbeing and glucose management of people with diabetes, and what healthcare professionals can do to help (15:48).

To begin our podcast series marking the 25th anniversary of the PSAD, we talk to founder Frank Snoek about its history and achievements, and the changing profile of psychosocial research in diabetes care (19:40).

DiRECT trial dietitian Alison Barnes discusses the challenges and triumphs of using a very-low-calorie, total-meal-replacement diet to help people with type 2 diabetes achieve weight loss and maintenance (25:34).

Listen to our Editorial Board reflecting on their ADA scientific highlights, and its novel virtual format (34:17).

Engineer turned endocrinologist Rayhan Lal reflects on the shape of artificial pancreas research and what changes are needed to best benefit people with diabetes (18:54).

US primary care physician Neil Skolnik discusses the role of oral semaglutide in the care of people with type 2 diabetes and outlines key considerations for its use (12:26).

The first author of the American Diabetes Association's 2019 consensus on nutrition therapy for adults with diabetes or prediabetes talks through the update and what it means for educators, practitioners and patients (22:17).

Medical sociologist Ashby Walker talks about a mentoring scheme pairing college students and teenagers who have type 1 diabetes - to the benefit of both (9:14).

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

medwireNews talks to one of the pioneers of closed-loop insulin delivery, Roman Hovorka, about his algorithm, his research so far, and his plans for commercialization.

medwireNews talks to Dan Finan from the JDRF about the artificial pancreas systems already in the pipeline, and how these are evolving in ways that might benefit particular groups of people with diabetes.

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

How will the findings of the REWIND trial and the DECLARE-TIMI 58 renal outcomes analysis affect treatment decisions for high-risk diabetes patients without overt cardiovascular disease? medwireNews asks Kamlesh Khunti.

The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.

Escalating obesity prevalence and severity has led to type 2 diabetes being diagnosed in ever-younger people, including children. medwireNews rounds up the accumulating evidence suggesting a particularly severe diabetes course in these young people.

Consultant nephrologist Andrew Frankel tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

General practitioner Kevin Fernando talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective (4:43).

Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).